Pulse Biosciences, Inc (PLSE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 32/100 (MEDIUM), 29.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 17.12% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
- Pulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA Data
- Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
- Why Pulse Biosciences Stock Popped Today
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
- Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript
- Pulse Biosciences Q2 Earnings Call Highlights
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Pulse versus Nonpulse Corticosteroid Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized Clinical Trial (SAFER). — Am J Respir Crit Care Med 2026 Sep 30 PMID 42813947
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Pulse Biosciences, Inc.
Full PLSE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.